Company intelligence / Profile preview

RR MedSciences

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

RR MedSciences is an Australian clinical-stage biotechnology company focused on developing non-opioid treatments for chronic pain and inflammation. The company's lead candidate, RR-001, is a topical formulation designed to provide targeted relief for conditions such as neuropathic pain and post-herpetic neuralgia. By utilizing a unique mechanism that modulates reactive oxygen species and inflammatory pathways, RR MedSciences aims to offer effective pain management with reduced systemic side effects. The company is currently advancing its pipeline through Phase 2 clinical trials to address significant unmet needs in the global pain management market.

Therapeutic areas: NeurologyImmunology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

RM191A

Unknown

Beyond the preview

Go deeper on RR MedSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RR MedSciences.

Explore the full profile